Theregen Announces Equity Investment from Guidant Corporation to Develop Anginera(TM) Epicardial Patch

Theregen Corporation today announced that it has
received an equity investment from Guidant Corporation (NYSE:GDT), a
worldwide leader in the treatment of cardiovascular disease.
   Theregen is developing Anginera(TM) as a treatment for diffuse
small vessel coronary artery disease. In 2005, Theregen received FDA
approval to proceed with a Phase I safety trial for patients suffering
from this cardiovascular disorder. The product will serve as an
adjunct therapy to revascularization procedures that include coronary
artery bypass graft surgery. The company intends to initiate its
Anginera Phase I safety trial in this quarter.
   "We believe our Anginera(TM) therapy has the potential to benefit
patients suffering from a variety of chronic, debilitating
cardiovascular diseases," said Theregen CEO Thomas A. Schreck. "We are
very pleased to announce this strategic investment for Theregen, not
only due to the capital it affords to advance our clinical program,
but also for the access to highly regarded professionals within
Guidant."
   "We believe that Theregen's approach to delivering cell-based
therapies epicardially is promising. Guidant is pleased to be able to
support innovative technologies such as Anginera(TM) that hold the
opportunity to significantly improve the quality of life for patients
undergoing cardiac surgery procedures," said Maria Degois-Sainz,
President, Cardiac Surgery, Guidant.

   Theregen Corporation is a regenerative medicine company that
develops cell-based therapies for patients with cardiovascular and
vascular disease. Theregen's primary corporate objective is the
clinical development and approval of Anginera(TM), its lead product
candidate. Theregen is located in San Francisco, Calif., with research
and development facilities in Tucson, Ariz.

   Guidant Corporation, Indianapolis, Ind., pioneers lifesaving
technology, giving an opportunity for better life today to millions of
cardiac and vascular patients worldwide. The company develops,
manufactures and markets a broad array of products and services that
enable less invasive care for some of life's most threatening medical
conditions.